339 related articles for article (PubMed ID: 25935596)
1. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
Roozeboom MH; Nelemans PJ; Mosterd K; Steijlen PM; Arits AH; Kelleners-Smeets NW
Br J Dermatol; 2015 Mar; 172(3):739-45. PubMed ID: 25066012
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
[TBL] [Abstract][Full Text] [Related]
5. Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study.
van Delft LCJ; Nelemans PJ; Jansen MHE; Arits AHMM; Roozeboom MH; Hamid MA; Mosterd K; Kelleners-Smeets NWJ
J Am Acad Dermatol; 2019 Apr; 80(4):1022-1028. PubMed ID: 30582993
[TBL] [Abstract][Full Text] [Related]
6. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
[TBL] [Abstract][Full Text] [Related]
7. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial.
Roozeboom MH; Arits AHMM; Mosterd K; Sommer A; Essers BAB; de Rooij MJM; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
J Invest Dermatol; 2016 Aug; 136(8):1568-1574. PubMed ID: 27113429
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
Lecluse LL; Spuls PI
Br J Dermatol; 2015 Jan; 172(1):8-10. PubMed ID: 25581584
[TBL] [Abstract][Full Text] [Related]
9. Two-fold illumination in topical 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) for superficial basal cell carcinoma (sBCC): A retrospective case series and cohort study.
Kessels J; Hendriks J; Nelemans P; Mosterd K; Kelleners-Smeets N
J Am Acad Dermatol; 2016 May; 74(5):899-906. PubMed ID: 26774689
[TBL] [Abstract][Full Text] [Related]
10. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials.
Roozeboom MH; Arits AH; Nelemans PJ; Kelleners-Smeets NW
Br J Dermatol; 2012 Oct; 167(4):733-56. PubMed ID: 22612571
[TBL] [Abstract][Full Text] [Related]
11. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
Aguilar M; de Troya M; Martin L; Benítez N; González M
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response.
Fantini F; Greco A; Del Giovane C; Cesinaro AM; Venturini M; Zane C; Surrenti T; Peris K; Calzavara-Pinton PG
J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):896-901. PubMed ID: 21054566
[TBL] [Abstract][Full Text] [Related]
13. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC.
McKay KM; Sambrano BL; Fox PS; Bassett RL; Chon S; Prieto VG
Br J Dermatol; 2013 Sep; 169(3):549-54. PubMed ID: 23627639
[TBL] [Abstract][Full Text] [Related]
14. Facial extensive recurrent basal cell carcinoma: successful treatment with photodynamic therapy and imiquimod 5% cream.
Requena C; Messeguer F; Llombart B; Serra-Guillén C; Guillén C
Int J Dermatol; 2012 Apr; 51(4):451-4. PubMed ID: 22435437
[TBL] [Abstract][Full Text] [Related]
15. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up.
Szeimies RM; Ibbotson S; Murrell DF; Rubel D; Frambach Y; de Berker D; Dummer R; Kerrouche N; Villemagne H;
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1302-11. PubMed ID: 18624836
[TBL] [Abstract][Full Text] [Related]
16. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.
Jansen MHE; Mosterd K; Arits AHMM; Roozeboom MH; Sommer A; Essers BAB; van Pelt HPA; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
J Invest Dermatol; 2018 Mar; 138(3):527-533. PubMed ID: 29045820
[TBL] [Abstract][Full Text] [Related]
17. Commentary on 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial'.
Nijsten T
Br J Dermatol; 2015 Jan; 172(1):12. PubMed ID: 25581586
[No Abstract] [Full Text] [Related]
18. Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'.
Arits A; Nelemans P; Kelleners-Smeets N
Br J Dermatol; 2015 Jan; 172(1):11-2. PubMed ID: 25581585
[No Abstract] [Full Text] [Related]
19. Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream.
Devirgiliis V; Panasiti V; Curzio M; Gobbi S; Rossi M; Roberti V; Calvieri S
Dermatol Online J; 2008 Feb; 14(2):25. PubMed ID: 18700128
[No Abstract] [Full Text] [Related]
20. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers.
Tarstedt M; Gillstedt M; Wennberg Larkö AM; Paoli J
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):420-3. PubMed ID: 26841041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
